Pharmaceutical Technology's Annual Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Annual Employment Survey
Nearly 1300 pharmaceutical employees provide insights into the issues most relevant to their jobs and the state of the industry workforce today.


Pharmaceutical Technology



Figure 6. Mean annual base salaries since 1998.
Income, geographic location, the opportunity for professional advancement, and the balance between work and personal life were the most important factors that would be taken into consideration changing employment. Scientific opportunities was the least important, followed by commute time, vacation time, health and safety, and geographic location. Survey participants anonymously described what they enjoyed best and least in their jobs. Although the intellectual challenge was ranked as one of the least important factors in considering a new job, it was by far the most enjoyable part of working in the industry. Survey participants listed their work with colleagues, new technologies, and the satisfaction from completed projects. Judging from readers' responses, it was clear that the industry's workforce is passionate about the industry's long-term scientific goals. One quality assurance employee responded, "As QA, I enjoy the challenge of solving problems every day. QA work with different departments, issues that we face daily are quite different...there is no moment for getting bored!"

Following this question, we asked participants to describe what they least enjoyed about their jobs. Workers complained of increasing responsibilities, including extensive and repetitive paperwork, with shortened timelines. There were also several who were unsure about the economic health of their company and the security of their job, and several others who complained about the commute and not having enough time with family. Others are frustrated over management and corporate politics. When asked to describe the least enjoyable aspects of the job was the lease enjoyable, one respondent replied, "Too many layers of management and risk-adverse attitudes. Somewhere what made people successful in the first place, good decision making, has turned into paralysis."


Table V: Importance of various skills in performing daily tasks.
Preferred employer. Pharmaceutical industry employees appear to be determined to stay in their current position. About 67% said it was unlikely or very unlikely that they will change employment within the next year. If they were to make job changes, however, nearly 70% of respondents would prefer to work in private industry over any other sector, including nonprofit agencies, academic institutions, or government.


Table VI: Influence of regulatory guidelines.
Essential skills and knowledge. Participants weighed in on the importance of knowledge and skills in various areas (see Table V). At the list was knowledge of GMP issues and process validation. Respondents also indicated their awareness of FDA's "Quality by Design" (QbD) approach, process analytical technology (PAT) initiative, and 21 CFR Part 11 rule (see Table VI). Although most respondents indicated they were very aware of the QbD and Part 11 initiatives, only 35% said the same about FDA's PAT guideline. Perhaps not surprisingly, the direct impact these initiatives have had on the job performance has not changed over last year.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here